RT Journal Article
SR Electronic
T1 Duovent – is logic enough?
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 3
OP 4
DO 10.1136/dtb.23.1.3
VO 23
IS 1
YR 1985
UL http://dtb.bmj.com/content/23/1/3.abstract
AB Duovent (WB Pharmaceuticals) is a fixed-dose combination aerosol containing fenoterol (100 μg per puff) - a β2-adrenoceptor stimulant, and ipratropium (40 μg per puff) - an atropine-like agent. It is marketed for the treatment of bronchoconstriction in patients with asthma, chronic bronchitis or emphysema. The manufacturer claims that it is a ‘logical combination’ offering ‘first line treatment’, but the British National Formulary1 states that compound bronchodilators (including Duovent) ‘have no place in the management of patients with airways obstruction’.